CRISM Therapeutics Corporation Working Capital to Net Assets Ratio
CRISM Therapeutics Corporation working capital to net assets ratio. CRISM Therapeutics Corporation (CRTX) has a Working Capital to Net Assets ratio of 94.5% as of June 2026. Working capital of GBX2.44 Million (current assets of GBX2.78 Million minus current liabilities of GBX343.00K) is measured against net assets of GBX2.58 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of CRISM Therapeutics Corporation (2006–2025)
Working capital to net assets ratio of CRISM Therapeutics Corporation from 2006 to 2025. This chart shows how CRISM Therapeutics Corporation's Working Capital to Net Assets ratio has evolved across 20 annual periods from 2006 to 2025. As of June 2026, the ratio stands at 94.5%, reflecting working capital of GBX2.44 Million against net assets of GBX2.58 Million GBX. See CRISM Therapeutics Corporation defensive interval ratio to measure how many days the company can operate on defensive assets alone.
CRISM Therapeutics Corporation Working Capital to Net Assets Ratio by Year (2006–2025)
CRISM Therapeutics Corporation working capital to net assets ratio by year from 2006 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for CRISM Therapeutics Corporation from 2006 to 2025, covering 20 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see CRTX total assets.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 90.1% | GBX1.28 Million | GBX1.42 Million | GBX1.66 Million | GBX381.00K | ▼ -1.3 pp |
| 2024 | 91.5% | GBX1.35 Million | GBX1.48 Million | GBX1.69 Million | GBX341.00K | ▲ +22.6 pp |
| 2023 | 68.8% | GBX-522.94K | GBX-759.66K | GBX13.00K | GBX535.94K | ▲ +58.8 pp |
| 2022 | 10.1% | GBX2.33 Million | GBX23.13 Million | GBX2.95 Million | GBX619.34K | ▼ -3.4 pp |
| 2021 | 13.4% | GBX4.05 Million | GBX30.11 Million | GBX5.01 Million | GBX964.05K | ▲ +6.3 pp |
| 2020 | 7.2% | GBX2.24 Million | GBX31.35 Million | GBX3.15 Million | GBX913.00K | ▲ +7.4 pp |
| 2019 | -0.3% | GBX-60.39K | GBX20.48 Million | GBX668.05K | GBX728.44K | ▲ +3.6 pp |
| 2018 | -3.9% | GBX-913.00K | GBX23.48 Million | GBX1.71 Million | GBX2.62 Million | ▼ -15.6 pp |
| 2017 | 11.7% | GBX3.30 Million | GBX28.20 Million | GBX4.07 Million | GBX768.00K | ▼ -11.8 pp |
| 2016 | 23.5% | GBX6.01 Million | GBX25.55 Million | GBX9.72 Million | GBX3.71 Million | ▼ -23.0 pp |
| 2015 | 46.5% | GBX7.07 Million | GBX15.21 Million | GBX7.68 Million | GBX615.14K | ▲ +3.9 pp |
| 2014 | 42.6% | GBX8.83 Million | GBX20.72 Million | GBX9.09 Million | GBX261.02K | ▲ +6.0 pp |
| 2013 | 36.6% | GBX6.61 Million | GBX18.05 Million | GBX6.68 Million | GBX74.25K | ▲ +5.1 pp |
| 2012 | 31.6% | GBX5.09 Million | GBX16.12 Million | GBX5.16 Million | GBX73.21K | ▲ +9.4 pp |
| 2011 | 22.1% | GBX4.69 Million | GBX21.19 Million | GBX4.75 Million | GBX65.63K | ▲ +1.0 pp |
| 2010 | 21.1% | GBX4.50 Million | GBX21.29 Million | GBX4.61 Million | GBX109.60K | ▲ +14.2 pp |
| 2009 | 6.9% | GBX1.14 Million | GBX16.52 Million | GBX1.43 Million | GBX289.43K | ▲ +1.4 pp |
| 2008 | 5.6% | GBX598.85K | GBX10.78 Million | GBX890.98K | GBX292.12K | ▼ -5.6 pp |
| 2007 | 11.1% | GBX727.42K | GBX6.53 Million | GBX902.74K | GBX175.32K | ▼ -21.5 pp |
| 2006 | 32.6% | GBX3.05 Million | GBX9.33 Million | GBX3.06 Million | GBX15.71K | — |